Duffy Sean P. sold $509K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 21,572 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($23.12–$24.27, $0.51M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Bearish
medium confidence
Mentioned
$OMDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDABearishLow
01

Why it matters

The disclosed sale adds slight bearish pressure but is unlikely to move the stock significantly.

02

Market read

Primary relevance is to traders monitoring insider activity; limited broader market effect.

03

What to watch

CEO may be diversifying personal assets; the 10b5‑1 plan pre‑arranged.

Relevance 4/10Novelty 4/10Timing: Filed 2026‑09‑03, reflecting a sale on 2026‑09‑01.

Background

Form 4 filing discloses insider transactions required by SEC; provides first public notice of the sale.

Company-level read

Ticker impact

$OMDABearishMedium confidence
Context

CEO Sean P. Duffy sold 21,572 shares for $509,465 via a 10b5‑1 plan on 2026‑09‑01.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

Sale size is modest relative to holdings, but insider sales often trigger sell‑side bias.

Market effects

Minimal impact on digital health sector; similar insider sales have limited ripple.

U.S. market only; no broader regional effect.

Low; the filing is company‑specific.

Counterpoint

The sale could be routine liquidity planning, not a lack of confidence.

Key entities

  • Omada Health, Inc.

    Digital health platform listed on Nasdaq under ticker OMDA.

  • Sean P. Duffy

    Chief Executive Officer of Omada Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.